|
23andMe Holding Co. (ME) تقييم DCF |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
23andMe Holding Co. (ME) Bundle
هندسة من أجل الدقة ، تمكنك حاسبة DCF الخاصة بنا (ME) لدينا من تقييم تقييم 23andme Holding Co. باستخدام البيانات المالية الفعلية ، مع تقديم مرونة كاملة لتعديل جميع المعلمات الأساسية للتنبؤات المحسنة.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305.5 | 243.9 | 271.9 | 299.5 | 219.6 | 205.8 | 192.8 | 180.7 | 169.3 | 158.7 |
| Revenue Growth, % | 0 | -20.15 | 11.47 | 10.15 | -26.66 | -6.3 | -6.3 | -6.3 | -6.3 | -6.3 |
| EBITDA | -191.5 | -165.0 | -228.0 | -291.9 | -291.9 | -169.4 | -158.8 | -148.8 | -139.4 | -130.6 |
| EBITDA, % | -62.69 | -67.62 | -83.86 | -97.48 | -132.89 | -82.33 | -82.33 | -82.33 | -82.33 | -82.33 |
| Depreciation | 22.2 | 20.2 | 26.1 | 36.5 | 29.5 | 20.9 | 19.6 | 18.4 | 17.2 | 16.1 |
| Depreciation, % | 7.28 | 8.3 | 9.62 | 12.19 | 13.42 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 |
| EBIT | -213.8 | -185.2 | -254.2 | -328.4 | -321.4 | -180.9 | -169.5 | -158.8 | -148.8 | -139.4 |
| EBIT, % | -69.98 | -75.92 | -93.48 | -109.67 | -146.31 | -87.88 | -87.88 | -87.88 | -87.88 | -87.88 |
| Total Cash | 209.3 | 282.5 | 553.2 | 386.8 | 217.9 | 192.5 | 180.4 | 169.0 | 158.4 | 148.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 6.4 | 2.5 | 3.4 | 1.9 | 9.1 | 3.8 | 3.5 | 3.3 | 3.1 | 2.9 |
| Account Receivables, % | 2.09 | 1.02 | 1.24 | 0.63341 | 4.13 | 1.82 | 1.82 | 1.82 | 1.82 | 1.82 |
| Inventories | 14.1 | 6.2 | 10.8 | 10.2 | 12.5 | 8.3 | 7.8 | 7.3 | 6.9 | 6.4 |
| Inventories, % | 4.62 | 2.56 | 3.97 | 3.42 | 5.68 | 4.05 | 4.05 | 4.05 | 4.05 | 4.05 |
| Accounts Payable | 13.1 | 12.3 | 37.9 | 12.9 | 11.6 | 13.5 | 12.7 | 11.9 | 11.1 | 10.4 |
| Accounts Payable, % | 4.28 | 5.03 | 13.95 | 4.32 | 5.27 | 6.57 | 6.57 | 6.57 | 6.57 | 6.57 |
| Capital Expenditure | -73.6 | -7.4 | -14.0 | -11.3 | -1.1 | -15.0 | -14.1 | -13.2 | -12.4 | -11.6 |
| Capital Expenditure, % | -24.09 | -3.02 | -5.14 | -3.77 | -0.51403 | -7.31 | -7.31 | -7.31 | -7.31 | -7.31 |
| Tax Rate, % | -0.01095059 | -0.01095059 | -0.01095059 | -0.01095059 | -0.01095059 | -0.01095059 | -0.01095059 | -0.01095059 | -0.01095059 | -0.01095059 |
| EBITAT | -246.5 | -184.9 | -250.2 | -325.5 | -321.4 | -179.9 | -168.6 | -158.0 | -148.0 | -138.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -305.3 | -161.1 | -217.8 | -323.3 | -303.8 | -162.6 | -163.2 | -152.9 | -143.3 | -134.2 |
| WACC, % | 4.87 | 4.87 | 4.82 | 4.85 | 4.87 | 4.86 | 4.86 | 4.86 | 4.86 | 4.86 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -660.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -137 | |||||||||
| Terminal Value | -4,792 | |||||||||
| Present Terminal Value | -3,780 | |||||||||
| Enterprise Value | -4,441 | |||||||||
| Net Debt | -140 | |||||||||
| Equity Value | -4,301 | |||||||||
| Diluted Shares Outstanding, MM | 24 | |||||||||
| Equity Value Per Share | -180.70 |
What You Will Get
- Comprehensive 23andMe Data: Access historical and projected genetic research insights for informed decision-making.
- Customizable Parameters: Adjust variables such as research funding, growth rates, and market penetration.
- Dynamic Calculations: Key metrics like market potential and ROI are computed in real-time.
- Scenario Simulation: Explore various scenarios to assess 23andMe's future growth prospects.
- User-Friendly Interface: Designed for industry experts but easy for newcomers to navigate.
Key Features
- Comprehensive Genetic Data: Access to extensive genetic insights and reports.
- User-Friendly Interface: Simple navigation for users to explore their genetic information.
- Real-Time Updates: Receive notifications for new discoveries and updates on your genetic data.
- Visual Representation: Interactive charts and graphs to illustrate genetic traits and ancestry.
- Designed for Personalization: Tailored health and ancestry reports for individuals seeking deeper insights.
How It Works
- Download: Obtain the pre-built Excel file containing 23andMe Holding Co.'s (ME) financial data.
- Customize: Modify projections, including customer growth, revenue margins, and discount rates.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and analyze results instantly.
- Make Decisions: Leverage the valuation insights to inform your investment approach.
Why Choose 23andMe Holding Co. (ME)?
- Personalized Insights: Gain tailored genetic information that empowers your health decisions.
- Cutting-Edge Technology: Utilize advanced genetic testing methods for accurate results.
- Comprehensive Reports: Access detailed reports that cover ancestry, traits, and health risks.
- User-Friendly Experience: Enjoy an intuitive platform that makes understanding your genetics simple.
- Backed by Science: Rely on research-driven insights from a trusted leader in genetic testing.
Who Should Use This Product?
- Genetic Researchers: Develop comprehensive genetic analysis models for study and research purposes.
- Healthcare Professionals: Evaluate genetic data to inform patient care and treatment strategies.
- Consultants and Advisors: Offer clients informed insights into genetic testing and its implications for health.
- Students and Educators: Utilize real-world genetic data to enhance learning and teaching in genetics.
- Biotech Enthusiasts: Gain an understanding of how companies like 23andMe Holding Co. (ME) are shaping the future of personalized medicine.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring intricate valuation calculations.
- Real-World Data: 23andMe's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.